I am keeping a close eye on (Nasdaq: IXHL) (ASX: IHL) as they...

I am keeping a close eye on (Nasdaq: IXHL) (ASX: IHL) as they announce the progress of their Phase 2 trial, PsiGAD1, for the treatment of generalised anxiety disorder (GAD) using psilocybin-assisted psychotherapy. The trial has achieved its interim milestone of 29 patients completing primary endpoint assessments and independent analysis of the interim study data has begun. With the potential for a promising treatment for GAD, where current medications and therapies are inadequate, I am bullish on the stock's performance. I see a nice steady run to $0.26 and a re-test of $0.22.5 in the near future. However, as always, it's important to do one's own research and stick to one's trading/ Invesment plan. 100% its a long hold for me ...